Monoclonal antibody · developed by Dianthus Therapeutics
Claseprubart (DNTH103) is a drug studied in chronic inflammatory demyelinating polyneuropathy, a chronic immune-mediated disorder of the peripheral nerves.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06858579 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | DNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Inflammatory Demyelinating Polyneuropathy
See DNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
DNTH catalysts and pipeline →